• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can CA-125/CEA ratio be used for the differential diagnosis between ovarian and nonovarian cancers? A research letter.

作者信息

Zanon Jeferson R, Simioni Elisa B, Barbin Flávia F, Pedrão Priscila G, Andrade Carlos E M C, de Andrade Diocésio A P, Bilibio João P, Fregnani José H T G, Dos Reis Ricardo

机构信息

Department of Nephrology and Palliative Care at Jales Cancer Hospital (a Barretos Cancer Hospital Unit - Pio XII Foundation), Jales.

Department of Gynecologic Oncology at Jaú Cancer Hospital (Amaral Carvalho Foundation), Jaú.

出版信息

Int J Surg. 2024 Nov 1;110(11):7397-7400. doi: 10.1097/JS9.0000000000002015.

DOI:10.1097/JS9.0000000000002015
PMID:39166953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11573086/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/1dcf1bba7682/js9-110-7397-s003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/7ae6ab7e9519/js9-110-7397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/2eb1e52977f5/js9-110-7397-s002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/1dcf1bba7682/js9-110-7397-s003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/7ae6ab7e9519/js9-110-7397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/2eb1e52977f5/js9-110-7397-s002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa8/11573086/1dcf1bba7682/js9-110-7397-s003.jpg

相似文献

1
Can CA-125/CEA ratio be used for the differential diagnosis between ovarian and nonovarian cancers? A research letter.CA-125/CEA 比值能否用于卵巢癌与非卵巢癌的鉴别诊断？一封研究信。
Int J Surg. 2024 Nov 1;110(11):7397-7400. doi: 10.1097/JS9.0000000000002015.
2
When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.当卵巢癌并非如此时：在腹腔镜为基础的分诊系统中对非卵巢癌病理进行特征描述。
Int J Gynecol Cancer. 2018 Oct;28(8):1485-1490. doi: 10.1097/IGC.0000000000001329.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
5
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
6
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗：一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
7
Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia.用于检测疑似痴呆患者额颞叶痴呆的局部脑血流单光子发射计算机断层扫描
Cochrane Database Syst Rev. 2015 Jun 23;2015(6):CD010896. doi: 10.1002/14651858.CD010896.pub2.
8
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.术中冰冻切片分析用于诊断可疑盆腔肿块中的早期卵巢癌。
Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2.
9
Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.长效注射与每日给药的促性腺激素释放激素激动剂方案用于辅助生殖周期中垂体降调节的比较
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD002808. doi: 10.1002/14651858.CD002808.pub3.
10
Blood biomarkers for the non-invasive diagnosis of endometriosis.用于子宫内膜异位症无创诊断的血液生物标志物。
Cochrane Database Syst Rev. 2016 May 1;2016(5):CD012179. doi: 10.1002/14651858.CD012179.

本文引用的文献

1
Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.弥散加权磁共振序列和 CA125/CEA 比值可作为超声的附加工具，用于区分卵巢和非卵巢盆腔肿块。
PLoS One. 2023 Mar 16;18(3):e0283212. doi: 10.1371/journal.pone.0283212. eCollection 2023.
2
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist.血清肿瘤标志物在卵巢癌管理中的过去、现在和未来：放射科医生的指南。
Radiographics. 2021 Oct;41(6):1839-1856. doi: 10.1148/rg.2021210005.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.ESMO-ESGO 共识会议关于卵巢癌的建议：病理学和分子生物学，早期和晚期，交界性肿瘤和复发性疾病†。
Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
5
The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.CA 125作为肿瘤标志物的作用：生化及临床方面
Adv Exp Med Biol. 2015;867:229-44. doi: 10.1007/978-94-017-7215-0_14.
6
Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis.癌抗原125和癌胚抗原联合检测可提高卵巢癌诊断水平。
Dan Med Bull. 2011 Nov;58(11):A4331.
7
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
8
Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.通过使用CA 125与癌胚抗原的比值提高CA 125酶免疫测定法对卵巢癌的特异性。
Clin Chem. 1988 Sep;34(9):1853-7.
9
Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer.
J Surg Oncol. 1990 Jun;44(2):97-9. doi: 10.1002/jso.2930440207.
10
Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.血清肿瘤标志物在卵巢腺癌与结直肠癌鉴别诊断中的应用。
Tumour Biol. 1992;13(1-2):18-26. doi: 10.1159/000217748.